Psychiatr. praxi. 2013;14(3):102-104

Psychiatrists attitude to antipsychotic depot treatment

prof.MUDr.Eva Češková, CSc.
Psychiatrická klinika LF MU a FN Brno

At first history and current use of treatment with depot antipsychotics (AP) is summarized. Nowadays also the 2nd generation APs in

depot formulation are available. With long-term treatment the depot APs are better in the relapse prevention in comparison with oral

APs. Because psychiatrists diagnose and choose the treatment, their attitudes to different formulations of treatment are important.

Psychiatrists seem to use depots in a conservative way and mostly introduce them after several episodes and for reasons of nonadherence.

Patients should be informed about different forms of treatment during early stages of the illness and they should be involved in

the decision for a certain treatment form.

Keywords: schizophrenia, depot antipsychotics, nonadherence, attitudes to depots

Published: August 7, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Češková E. Psychiatrists attitude to antipsychotic depot treatment. Psychiatr. praxi. 2013;14(3):102-104.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Davis J M, Matalon L, Watanabe MD, Blake L, Metadon L. Depot antipsychotic drugs place in therapy. Drugs 1994; 47: 741-773. Go to original source... Go to PubMed...
    2. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a diference between typice and atypical agents? Am J Psychiatry 2002; 159: 103-108. Go to original source... Go to PubMed...
    3. Hasan A, Falkai P, Wobrock T, et al. WFSBP Task force on Treatment Guidelines for Schizophrenia. Word Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological treatment of Schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 2013; 14: 2-44. Go to original source... Go to PubMed...
    4. Grimaldi-Bensouda L, Rouillon F, Astrue B, et al. Does long-acting injectable risperidone make a difference to the real life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). Schizophr Res 2011; 134: 187-194. Go to original source... Go to PubMed...
    5. Weiden PJ, Schiller NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. J Clin Psychiatry 2009; 70: 1397-1406. Go to original source... Go to PubMed...
    6. Emsley R, Oosthuizen P, Koen L, et al. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. Int Clin Psychopharmacol 2008; 23: 325-331. Go to original source... Go to PubMed...
    7. Kissling W, Glue P, Medori R, Simpson S. Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients. Hum Psychopharmacol 2007; 22: 505-513. Go to original source... Go to PubMed...
    8. Fleischhacker WW, Gopal S, Lane R, et al. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol 2011; 22: 1-12. Go to original source...
    9. Kane JM, Derme HC, Naber D, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 2010; 167: 181-189. Go to original source... Go to PubMed...
    10. Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia - a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 2011; 127: 83-92. Go to original source... Go to PubMed...
    11. Hogarthy E, Schooler N, Ulrich R, et al. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry 1979; 36: 1283-1294. Go to original source... Go to PubMed...
    12. Češková E, Pečeňák J, Tůma I, Mohr P, Anders M. Účinnost dlouhodobě působících injekcí risperidonu (Risperdal Consta) v léčbě schizofrenní a schizoafektivní poruchy: dvouleté výsledky studie e-STAR v České a Slovenské republice. Čes a slov Psychiat 2011; 107: 137-143.
    13. Glazer WM. The depot paradox. Behav Health 2007; 27: 44-46.
    14. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalisation among California Medicaid patients with schizophrenia. Psychiatr Serv 2004; 55: 886-891. Go to original source... Go to PubMed...
    15. Jaeger M, Roster W. Attitudes towards long-acting depot antipsychotics: A survey of patients, relatives and psychiatrists. Psychiatry Res 2010; 175: 58-62. Go to original source... Go to PubMed...
    16. Valenstein M, Ganozcy D, McCarthy JF, Myra Kim H, Lee TA, Blow FC. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry 2006; 67: 1542-1550. Go to original source... Go to PubMed...
    17. Young JL, Zonana HV, Shepler L. Medication noncompliance in schizophrenia: modification and update. Bull Am Acad Psychiatry Law 1986; 14: 105-122. Go to PubMed...
    18. Young JL, Spitz TR, Hillbrand M, Dancri G. Medication adherence failure in schizophrenia: a forensic review of rates, reasons, treatments and prospects. Bull Am Acad Psychiatry Law 1999; 27: 426-444.
    19. Skinner TC, Barnard K, Cradock S, Parkin T. Patient and professional accuracy of recalled treatment decisions in outpatient consultation. Diabetic Medicine 2007; 24: 557-560. Go to original source... Go to PubMed...
    20. Lambert T, Brennan A, Castle D, Kelly DL, Conley RR. Perception of depot antipsychotics by mental health professionals. J Psychiatr Pract 2003; 9: 252-260. Go to original source... Go to PubMed...
    21. Byerly M, Fisher R, Whatley K, et al. A comparison of electronic monitoring vs clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Res 2005; 133: 129-133. Go to original source... Go to PubMed...
    22. Heres S, Hamann J, Kipling W, Leucht S. Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry 2006; 67: 1948-1953. Go to original source... Go to PubMed...
    23. Heres S, Schmitz FS, Leucht S, Palonk FG. The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol 2007; 22: 275-282. Go to original source... Go to PubMed...
    24. Waddell L, Tailor M. Attitudes of patients and mental health start to antipsychotic long-acting injections: a systematic review. Br J Psychiatry 2009; 52(suppl): S43-50. Go to original source... Go to PubMed...
    25. Walburn J, Gray R, Gournay K, Quraishi S, David AS. Systematic review of patient and nurse attitudes in depot antipsychotic medication. Br J Psychiatry 2001; 179: 300-307. Go to original source... Go to PubMed...
    26. Patel MX, Hamad PM, Chaudhry IB, et al. Psychiatrists use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years. J Psychopharmacol 2010; 24: 1473-1482. Go to original source... Go to PubMed...
    27. Patel MX, Nikolaou V, David AS. Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychol Med 2003; 33: 83-89. Go to original source... Go to PubMed...
    28. Patel MX, De Zoysa N, Baker D, David AS. Antipsychotic depot medication and attitudes of community psychiatric nurses. J Psychiatr Ment Health Nurs 2005; 12: 237-244. Go to original source... Go to PubMed...
    29. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorders. Am J Psychiatry 1999; 156: 544-549. Go to original source... Go to PubMed...
    30. Kane JM, Quitkin F, Rifkin A, et al. Fluphenazine versus placebo in patients with remitted acute first episode schizophrenia. Arch Gen Psychiatry 1982; 39: 70-73. Go to original source... Go to PubMed...
    31. Robinson DG, Woerner MG, Delman HM, Kane JM. Pharmacological treatments for first-episode schizophrenia. Schizophr Bull 2005; 31: 705-722. Go to original source... Go to PubMed...
    32. Heres S, Reichhart T, Hamann J, et al. Psychiatrists attitude to antipsychotic depot treatment in patients with first-episode schizophrenia. Eur Psychiatry 2011; 26: 297-301. Go to original source... Go to PubMed...
    33. Kane JM, Garcia-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections. Br J Psychiatry 2009; 195(suppl): S63-67. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.